Escin IA

Overview

Escin IA is an oral LOXL2 inhibitor and EMT inhibitor, with selectivity for LOXL2 -expressing cells. Escin IA suppresses invasion, migration, and metastasis of breast cancer cells, and acts as the primary anti-TNBC metastasis constituent of Aesculus chinensis Bunge fruit saponin fraction. Escin IA can be used for the research of triple-negative breast cancer , acute inflammation, and ethanol-induced gastric mucosal lesions.

Application

Products | Products > Disease Areas > Gastric Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HIV Protease | Products > Signaling Pathways > Monoamine Oxidase

Product Information

• Catalog No.: HY-N0554
• CAS No.: 123748-68-5
• Molecular Formula: C55H86O24
• Molecular Weight: 1131.26
• Purity: 99.59%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.5 mg/mL (2.21 mM); Clear solution
• Availability: In-stock

Source

Original product source